Trials / Completed
CompletedNCT04991506
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Elpiscience Biopharma, Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1 checkpoint inhibitor) in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ES102 | The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4) |
| DRUG | JS001 | JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle. |
Timeline
- Start date
- 2021-10-15
- Primary completion
- 2024-05-17
- Completion
- 2024-05-17
- First posted
- 2021-08-05
- Last updated
- 2025-06-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04991506. Inclusion in this directory is not an endorsement.